Skip to main content
Premium Trial:

Request an Annual Quote

Hannes Smarason, Stephen Martin, Gregory Landes, Craig Mello, Melvin Booth, Jose Baselga, Suzanne Mattingly, Jay Flatley, Sally Brashears, Mark Kay, Jo Milner, Robert Lanford, David Russell


Hannes Smarason has left his post at Decode Genetics as executive vice president and senior business officer. He will become chairman of the board of Icelandair. Smarason will continue to work with Decode as a consultant.

Applied Biosystems alumnus Stephen Martin has been named senior vice president and chief technical officer of Beyond Genomics. He was senior director of the Discovery Proteomics and Small Molecule Research Center at ABI. Martin holds a PhD in analytical chemistry from MIT and a BA in chemistry from Boston University.

Gregory Landes has joined Lexicon Genetics as vice president of biotherapeutics. In the past, he was vice president of product discovery at Abgenix and vice president of genetics and genomics at Genzyme. Landes holds a PhD in biochemistry and a BA in chemistry from the University of Kansas.

Craig Mello has become a scientific advisor for Invitrogen in the area of RNAi research. He is a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor’s degree in biochemistry from Brown University.

Melvin Booth has joined the board of directors of Millipore. Until his retirement in January, he was president and COO of MedImmune. Prior to that, he was president and COO of Human Genome Sciences. Booth holds a doctor of science degree from Northwest Missouri State University.

Aclara Biosciences has appointed Jose Baselga to its scientific advisory board. Baselga is professor of medicine at the Universidad Autonoma de Barcelona and the scientific chairman of the Spanish breast cancer cooperative group SOLTI. He is associate editor of the Annals of Oncology and a member of the editorial advisory board for Cancer Cell, Clinical Cancer Research and Investigational New Drugs.

Exagen Diagnostics has named Suzanne Mattingly to the position of vice president of business development and marketing. She will establish strategic business relationships with reference laboratories and pharmaceutical companies to develop and commercialize new sets of genomic markers for diagnostic testing and drug development. Mattingly joins Exagen from Fast Track Systems, where she directed marketing, new product planning, and communications.

Jay Flatley has joined the board of directors of GenVault, a San Diego-based biosample management company. Flatley is president and CEO of Illumina. Prior to that, he was president and CEO of Molecular Dynamics.

Sally Brashears has been appointed vice president for IP at Benitec, the Queensland, Australia-based company said last week. She recently worked as an outside US patent counsel to the National Stem Cell Center in Melbourne, Australia.

Further, Benitec has added Avocel co-founder Mark Kay, Jo Milner, and former Avocel SAB members Robert Lanford and David Russell to its scientific advisory board. Benitec acquired Avocel last month.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.